Drugs / KITE-197
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06079164 | Nov 2023 → Jul 2026 overdue | aggressive B-cell non-Hodgkin lymphoma | Kite, A Gilead Company | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KITE-197 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06079164 ↗ |
| Modality | Cell therapy | “CAR-transduced autologous T cells” NCT06079164 ↗ |
| Route | Intravenous | “A single infusion of CAR-transduced autologous T cells administered intravenously” NCT06079164 ↗ |